us-website385aa2cb

Scalable, preventive heart care to reduce risk and cost

Wed, 08 Oct 2025 09:32:43 GMT

A pioneering collaboration between FibriCheck and U.K. private healthcare provider Benenden Health puts proactive heart rhythm monitoring directly in the hands of patients.

Benenden Health is known for offering quality, accessible healthcare to over 850,000 members. With heart rhythm disorders on the rise, early detection and remote monitoring became top priorities. But how do you scale that across a large, geographically dispersed member base?

That’s where FibriCheck steps in. With our scalable solution, we allow users to monitor their heart rhythm with just their smartphone. The implementation focused on ease-of-use, accessibility, and clinical reliability.

Through this partnership, Benenden Health integrated FibriCheck into their service offering, giving members access to:

Convenient, at-home heart rhythm checks at any time
Real-time results
Clinical-grade monitoring without the need for hardware
An easy way to share results with physicians for follow-up

Key benefits

The digital-first approach has led to earlier identification of heart rhythm conditions, improving outcomes and reducing unnecessary hospital visits .

Members report higher satisfaction and greater confidence in managing their health.

Early detection of heart rhythm conditions leads to a decrease in complications and treatment costs.

Attract new members and increase engagement by offering proactive heart care.

This is paragraph text. Click it or hit the Manage Text button to change the font, color, size, format, and more. To set up site-wide paragraph and title styles, go to Site Theme.

“Working with FibriCheck has been a fantastic step forward in helping our members look after their heart health. Since we launched the service, thousands of Benenden Health members have signed up and taken over 20,000 heart rhythm checks. Most results have been reassuring, but for some, it’s helped flag potential issues early—which is exactly why we introduced it. It’s been a great example of how digital tools can make a real difference, and we’re proud of what we’ve achieved together.”

— Neil Wilford, Product Manager, Benenden Health

Want to know more about what FibriCheck can mean for you? Contact us at explore@fibricheck.com

Our graduation from the TMCi accelerator

marketing@fibricheck.com (FibriCheck Marketing) — Wed, 04 Jun 2025 09:52:26 GMT

Over the past year, FibriCheck was proud to be part of the Texas Medical Center Innovation Factory ’ s accelerator program, a valuable experience that supported our U.S. business development journey.

As part of this program, we had the unique opportunity to connect with world-class clinical experts, mentors, and corporate partners across the largest medical city in the world. Through tailored guidance and access to top-tier hospitals, we engaged directly with electrophysiologists from the TMC Innovation network to test and validate our value in a real-world setting.

What being in this program together with other healthcare innovators brought us?

In-person presence at TMCi gave us a unique opportunity to immerse ourselves in the largest U.S. health system hub, facilitating deeper connections and insights.
We had the honor to build direct relationships with clinicians, operational leaders, and administrators across Houston’s top institutions, enabling us to validate our value proposition and strategy.
We worked closely with dedicated coaches and TMCi advisors, who helped us refine our go-to-market positioning within complex US care ecosystems.
Leveraged the TMCi startup community to exchange lessons with other digital health founders navigating similar hurdles, especially around EHR integration, billing workflows.
Strengthened FibriCheck’s visibility in the U.S. market and laid the foundation for ongoing partnerships and U.S.-based pilots.

We’re grateful for the lessons learned and the community we’ve joined, and we’re excited to take the next steps in our U.S. business development!

From the first to the 20 millionth measurement - every measurement matters.

marketing@fibricheck.com (FibriCheck Marketing) — Wed, 21 May 2025 12:45:15 GMT

FibriCheck has recently surpassed 20 million heart rhythm measurements — a major milestone that reflects the growing global trust in our technology. Every measurement might make a difference, that is something CEO Lars Grieten can confirm as FibriCheck saved his father’s life when the app was still in its early stages.

In 2013, Lars’ father suffered his first stroke when he was barely 51 years old. He felt perfectly healthy at the time. Two years later fate struck again. In both cases, specialists at the hospital were unable to determine the cause of the problem. Lars was determined to overcome the limitations of hospital equipment through a software only solution. In cooperation with cardiologists from a Belgian hospital ( Ziekenhuis Oost- Limburg Genk ) , a prototype of the digital application - later called FibriCheck - was finished at that time.

When Lars’ dad felt unwell again two weeks after his second stroke, they monitored his heart rhythm with FibriCheck. The results were of enormous value. Unknowingly, his dad was suffering from atrial fibrillation, one of the most common cardiac arrhythmias. He immediately started an adapted treatment. Together with his cardiologist, they still closely follow up on his dad’s heart rhythm through the FibriCheck app.

That’s the power of data. FibriCheck saved Lars’ father’s life.

That’s why this milestone is more than just a number. We’re deeply grateful to our users and partners for their continued support throughout our journey. As we move forward, we remain committed to shaping the future of heart health through continuous innovation and further enhancements to our clinically validated algorithm and digital solutions.

Want to talk about the possibilities of FibriCheck? Make sure to contact us at explore @fibricheck.com .

Announcing a new collaboration with the Midwest Cardiovascular Institute

marketing@fibricheck.com (FibriCheck Marketing) — Thu, 08 May 2025 12:31:18 GMT

We’re proud to announce that the Midwest Cardiovascular Institute has launched a program with FibriCheck. MCI’s team consists of twenty of the most highly regarded cardiologists in the Chicagoland area. The team is fully dedicated to delivering the highest standard of cardiovascular care through a patient-first philosophy and clinical excellence.

As part of this initiative, the state-of-the-art, non-invasive PPG technology will be used to monitor patients following atrial fibrillation (AF) ablation procedures. This aligns seamlessly with MCI’s mission by enabling remote monitoring, offering continuous insights into patient health, and reducing the need for in-person consultations.

FibriCheck provides long-term rhythm, rate, and symptom insights enabling timely AF recurrence detection without additional hardware, strengthening MCI’s cardiac diagnostic toolbox with longitudinal insights. More specifically:

Heart rate/rhythm insights
Symptom/rhythm insights
Symptom/symptom severity insights

This partnership represents an important step forward in making heart health solutions more accessible, efficient, and data-driven across the region.

To learn more about implementing FibriCheck in your practice, contact us at explore@fibricheck.com

FibriCheck is now collaborating with Smart Meter, a leading technology provider for remote patient monitoring in the U.S.

marketing@fibricheck.com (FibriCheck Marketing) — Tue, 18 Mar 2025 12:45:20 GMT

FibriCheck’s integration into Smart Meter’s solution

BELGIUM - March 18, 2O25 - FibriCheck is taking another step in expanding its product in the U.S. market by collaborating with remote patient monitoring company Smart Meter . With this new partnership, FibriCheck and Smart Meter aim to supply U.S. healthcare providers with access to valuable heart rhythm data to support them in their clinical decision-making and ultimately helping patients receive the correct treatment early on.

FibriCheck’s technology for heart rhythm and heart rate monitoring is now integrated with U.S. remote patient monitoring company Smart Meter. This integration enables user-friendly heart health monitoring for U.S. patients from the comfort of their own homes. Healthcare providers have access to the data via Smart Meter solutions, which provides them with valuable heart rhythm data within their own workflow. By providing healthcare providers with longitudinal data on heart rhythm and heart rate, they are supported in their clinical-decision making. This ultimately benefits both physicians and patients, as physicians have easier access to structured data and can gain immediate insights into their patients’ heart health, while patients are guided towards the right therapy early on.

This integration is a stepping stone toward broader adoption and paves the way for expansion into RPM programs nationwide, enabling patients all over the U.S. to monitor their heart rhythm with clinical-grade technology right from their smartphone.

About Smart Meter

Smart Meter is the premier technology infrastructure provider for Remote Patient Monitoring (RPM) and patient engagement. We reliably deliver millions of near- real-time vital health readings from over 300,000 patients using our proprietary FDA registered cellular devices through our exclusive AT&T private data network. Trusted by thousands of healthcare service providers, Smart Meter is revolutionizing the way health data supports patient well-being and care. Learn more at www.SmartMeterRPM.com

Our participation in the AARP Accelerator program

marketing@fibricheck.com (FibriCheck Marketing) — Tue, 25 Feb 2025 12:45:12 GMT

FibriCheck has been accepted into the Agetech Collaborative ™ from the AARP® accelerator program, an 8-week program designed to elevate promising early-stage AgeTech startups. The AgeTech Collaborative™ from AARP® is an unparalleled innovation ecosystem bringing together cutting-edge thinkers in the longevity tech space to champion meaningful advances so that everyone can choose how they live as they age.

We’re proud to be a part of this AgeTech Collaborative community of startups, investors and partners. It is great to continue the conversation on how FibriCheck supports aging through monitoring and detecting heart rhythm disorders.

Talk to our business developer for more info: explore@fibricheck.com

FibriCheck ready to enter the U.S. market with FDA-clearance!

Wed, 24 Jul 2024 12:25:04 GMT

The Food and Drug Administration (FDA) cleared the FibriCheck application and portal for heart rhythm monitoring
FibriCheck is now the only FDA-cleared smartphone application for heart rhythm monitoring with ECG equivalence in the U.S.
FDA-clearance is an important stepping stone for FibriCheck’s further U.S. business development

HASSELT - July 24, 2024 After a rigorous investigation procedure by the Food and Drug Administration, FibriCheck is now FDA-cleared (K232804). This is an important milestone which supports FibriCheck’s further development in the U.S. market. The FDA-clearance also allows FibriCheck to improve current U.S. care pathways and to provide millions of Americans with the ability to just use their smartphone to obtain easy and accurate heart rhythm measurements. These measurements can enable the early detection and monitoring of heart rhythm conditions such as atrial fibrillation.

FibriCheck’s FDA-clearance

Qompium announced the FDA-clearance and commercial launch of FibriCheck for heart rhythm and heart rate measurements on the 24th of July 2024. With the FDA-clearance of the FibriCheck ecosystem, U.S. patients can now access FibriCheck on demand when prescribed by their physician.

The FibriCheck ecosystem consists of a patient-facing smartphone application, an algorithm powered by the latest generation of AI that has been trained on more than a million datasets, and a healthcare provider portal. The FDA-cleared FibriCheck ecosystem allows healthcare providers to follow up on the heart health of their patients remotely without the need for additional hardware. The results of the heart rhythm measurements performed with the FibriCheck application are shared directly through FibriCheck’s physician portal. This allows healthcare providers to redraw their current pathways by offering a digital first solution, enabling hybrid care models to support them in better clinical decision making.

FibriCheck is the only FDA-cleared smartphone application with ECG equivalence in the U.S.

During the past year, several algorithm updates provided substantial improvements to FibriCheck. Independent external validation studies showed that FibriCheck’s accuracy for detecting AF is excellent, with a sensitivity of 98.3% and a specificity of 99.9% (1) . These significant performance gains and improved capabilities led to another meaningful achievement, as FibriCheck outperformed rivaling state-of-the-art devices for heart rhythm monitoring, such as the Apple watch ECG and the KardiaMobile 6-lead handheld ECG (2) .

Thanks to the outstanding performance of 99% accuracy compared to gold-standard ECG in a recent clinical trial ( NCT06282380 ), FibriCheck was FDA-cleared within the category of smartphone ECG devices, named the DXH category. This makes FibriCheck the only smartphone application using PPG-technology that is FDA-cleared with equivalence to ECG. FibriCheck’s patented technology also demonstrated an equal performance across different comorbidities and skin tones.

FibriCheck ready to expand in the U.S. market

Since the beginning of this year, FibriCheck has increased its presence in the U.S. by opening a New York office, participating in the world renowned MedTech Innovator and by collaborating with renowned European and U.S. hospitals such as Northwestern Medicine Chicago, the New York Presbyterian, the University of Oklahoma College of Medicine, Hospital East-Limburg and Antwerp University Hospital.

This FDA-clearance is an important stepping stone for the further development of FibriCheck’s U.S. business activities. FibriCheck can now be prescribed in the U.S. and reimbursed using existing reimbursement codes. The clearance of the FDA for prescription use also plays an important part in FibriCheck’s future goal to support the entire patient journey and to be able to offer FibriCheck over-the-counter in the U.S.. This would make it possible for anyone in need to follow up on their heart rhythm and the symptoms they’re experiencing, with or without their physician involved.

Lars Grieten (CEO and co-founder) comments: “Receiving FDA clearance for a software-only application using consumer devices was a difficult challenge, but it showcases the competence and excellence of our team. This is just the beginning. Our achievement serves as a foundation for future growth as we continue to expand our capabilities based on our AI advancements. We are dedicated to redrawing the blueprint of heart rhythm disorder monitoring and management by paving the way to a healthier future, delivering the right diagnosis to the right person at the right time. Together, we dream of making solutions that are not dependent on specific hardware or devices, so that digital health can truly fulfill its promise.”

About FibriCheck

FibriCheck’s medically certified technology redefines the way cardiac arrhythmias are detected and managed. FibriCheck transforms consumer devices such as smartphones into FDA-cleared medical devices capable of detecting atrial fibrillation and other arrhythmias, without logistical challenges or a need for additional hardware.

The data from FibriCheck’s intermittent and remote PPG-measurements is analyzed by FibriCheck’s AI algorithm, with additional review services by professionals. The data is shared immediately with FibriCheck’s physician portal, where healthcare providers can get an overview of their patients’ measurement results and gain insights into the heart rate, heart rhythm, and AF phenotype of their patients, including AF load, symptoms, symptom severity and symptom-rhythm correlation.

FibriCheck’s technology is currently being used by over 1 million users and has been implemented in over 20 different clinical pathways throughout numerous hospitals all over Europe, the UK, Australia and the Middle East, thereby supporting healthcare providers in their clinical decision making. FibriCheck has proven to be clinically superior to traditional care pathways and has demonstrated to be a user-friendly and scalable digital solution that is able to decrease wait lists, reduce costs, and improve efficiency both for healthcare providers and patients.

( 1) Gruwez et al. (2024). [Real-world validation of smartphone-based photoplethysmography for rate and rhythm monitoring in atrial fibrillation]( https://academic.oup.com/europace/article/26/4/euae065/7648812?login=false )

(2) Wouters et al. (2024). [PO-03-005 COMPARATIVE EVALUATION OF DIGITAL CONSUMER DEVICES FOR ATRIAL FIBRILLATION DETECTION: A VALIDATION STUDY] ( https://www.heartrhythmjournal.com/article/S1547-5271(24)01474-7/fulltext )

Press contact and materials

Contact for more information on this new FDA-clearance:

Lars Grieten

CEO FibriCheck

Lars.grieten@fibricheck.com

Download press materials such as our logo and imagery here .